InsiderTrades.com logo

David Parrot Biography and Net Worth

CFO of Scribe Therapeutics
  • LinkedIn
  • Phone
  • Website


David Parrot is the Chief Financial Officer at Scribe Therapeutics, bringing more than 30 years of experience as an Investment Banker advising Life Science Companies on raising capital and executing strategic transactions. David joined Scribe in December 2021 from Barclays, where he served as a managing director and was Head of West Coast Life Science Investment Banking. Before joining Barclays, David spent 11 years at Piper Jaffray as a senior member of the Biotechnology investment banking team. He was previously also a Managing Director at SunTrust Robinson Humphrey and BMO Capital Markets focused on advising private and public biopharma companies.

David earned a BA from Middlebury College and an MBA from the Haas School of Business at the University of California at Berkeley.

What is David Parrot's net worth?

The estimated net worth of David Parrot is at least $43.99 thousand as of July 23rd, 2026. Mr. Parrot owns 1,333 shares of Scribe Therapeutics stock worth more than $43,989 as of September 18th. This net worth approximation does not reflect any other investments that Mr. Parrot may own. Learn More about David Parrot's net worth.

How do I contact David Parrot?

The corporate mailing address for Mr. Parrot and other Scribe Therapeutics executives is 1150 Marina Village Pkwy, Alameda, CA, 94501. Scribe Therapeutics can also be reached via phone at (510) 454-0213. Learn More on David Parrot's contact information.

Has David Parrot been buying or selling shares of Scribe Therapeutics?

During the past quarter, David Parrot has bought $39,990.00 in shares of Scribe Therapeutics stock. Most recently, on Thursday, July 23rd, David Parrot bought 2,666 shares of Scribe Therapeutics stock. The stock was acquired at an average cost of $15.00 per share, with a total value of $39,990.00. Following the completion of the transaction, the chief financial officer now directly owns 1,333 shares of the company's stock, valued at $19,995. Learn More on David Parrot's trading history.

Who are Scribe Therapeutics' active insiders?

Scribe Therapeutics' insider roster includes Behzad Aghazadeh (Director), Carl Gordon (Director), and David Parrot (CFO). Learn More on Scribe Therapeutics' active insiders.

Are insiders buying or selling shares of Scribe Therapeutics?

During the last year, Scribe Therapeutics insiders bought shares 5 times. They purchased a total of 3,727,237 shares worth more than $56,291,746.20. The most recent insider tranaction occured on July, 28th when Director Behzad Aghazadeh bought 7,905 shares worth more than $144,266.25. Learn More about insider trades at Scribe Therapeutics.

Information on this page was last updated on 7/28/2026.

David Parrot Insider Trading History at Scribe Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/23/2026Buy2,666$15.00$39,990.001,333View SEC Filing Icon  
See Full Table

David Parrot Buying and Selling Activity at Scribe Therapeutics

This chart shows David Parrot's buying and selling at Scribe Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Scribe Therapeutics Company Overview

Scribe Therapeutics logo
Scribe Therapeutics Inc. is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Scribe Therapeutics Inc. is based in ALAMEDA, Calif.
Read More

Today's Range

Now: $33.00
Low: $31.76
High: $35.40

50 Day Range

MA: $26.95
Low: $18.06
High: $37.25

2 Week Range

Now: $33.00
Low: $17.31
High: $39.60

Volume

2,236,386 shs

Average Volume

210,506 shs

Market Capitalization

$624.69 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A